Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 459-467

  Liu, Fangfang ^a   Li, Yaqing ^a   Ren, Meijing ^a   Zhang, Xinmin ^b   Guo, Xiaojing ^a   Lang, Ronggang ^a   Gu, Feng ^a   Fu, Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast cancer; Chemotherapy; Regulatory T cell; Survival

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LETROZOLE; TAMOXIFEN; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84866528924     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2132-3     Document Type: Article

References (31)

1. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466 (Pubitemid 34260523)
2. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685 (Pubitemid 28363030)
3. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785 (Pubitemid 351264391)
4. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5:397-405 (Pubitemid 40637831)
5. Lake RA, van der Most RG (2006) A better way for a cancer cell to die. N Engl J Med 354:2503-2504 (Pubitemid 43855057)
6. Casares N, Pequignot MO, Tesniere A et al (2005) Caspasedependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691-1701 (Pubitemid 41815875)
7. Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61 (Pubitemid 46067386)
8. Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277 (Pubitemid 46202341)
9. Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059 (Pubitemid 47517504)
10. Bates GJ, Fox SB, Han C et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380 (Pubitemid 46623168)
11. Bohling SD, Allison KH (2008) Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 21:1527-1532
12. Gobert M, Treilleux I, Bendriss-Vermare N et al (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:2000-2009
13. Liu F, Lang R, Zhao J et al (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130:645-655
14. + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13:2714-2721 (Pubitemid 46788040)
15. + regulatory T cells. Clin Cancer Res 14:2413-2420 (Pubitemid 351551075)
16. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
17. Ogston KN, Miller ID, Payne S et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320-327 (Pubitemid 37322062)
18. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750
19. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684-1691
20. Curiel TJ, Coukos G, Zou LH et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949 (Pubitemid 39273735)
21. Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8(+) tumor-infiltrating lymphocytes and a high CD8(+)/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543 (Pubitemid 43011261)
22. Kobayashi N, Hiraoka N, Yamagami W et al (2007) FOXP3(+) regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902-911 (Pubitemid 46340366)
23. Gao Q, Qiu SJ, Fan J et al (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593 (Pubitemid 47041232)
24. Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3(+) regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423-5434 (Pubitemid 44497257)
25. Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964 (Pubitemid 44498003)
26. Dieu-Nosjean MC, Antoine M, Danel C et al (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410-4417
27. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186-192
28. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641-648 (Pubitemid 46348738)
29. Machiels JP, Reilly RT, Emens LA et al (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factorsecreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689-3697 (Pubitemid 32694981)
30. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F (2008) Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57:1579-1587
31. Gonzalez-Angulo AM, McGuire SE, Buchholz TA et al (2005) Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23:7098-7104